Abstract
This study evaluated the efficacy and safety of topotecan, a topoisomerase I inhibitor, in patients with advanced squamous cell cancer of the head and neck. Topotecan was administered intravenously (over 30 min) daily for 5 days every 3 weeks at a starting dose of 1.5 mg/m2/day. Eligibility required no prior chemotherapy, measurable disease, and performance status of < or = 2. Quality of life (QOL) assessment was performed at specified time points using the Spitzer QOL index and the symptom distress scale. Of 26 patients entered into the study, 23 and 22 patients were assessable for toxicity and response, respectively. One complete and two partial responses were observed, with response durations of 9, 4, and 1.5 months, respectively. Six patients had stable disease, including one patient with a 45% tumor shrinkage. The median survival for all patients entered was 4 months. Neutropenia was the major dose-limiting side effect, with grade 4 toxicity observed in 42% of all cycles of treatment. Grade 3 anemia occurred in 16% of all cycles, and nine patients required blood transfusions. Nonhematologic toxicities were infrequent and mild to moderate. QOL assessment revealed no significant change of total scores between each assessment...Continue Reading
References
Oct 1, 1978·Cancer Nursing·R McCorkle, K Young
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·J H KimM S Khil
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A ForastiereS K Williamson
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C JacobsL Schacter
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E J KatzS B Howell
Jan 1, 1985·Cancer Chemotherapy and Pharmacology·R P MortonP M Stell
Dec 17, 1989·Biochimica Et Biophysica Acta·P D'Arpa, L F Liu
Mar 15, 1986·Cancer·E TapazoglouM Al-Sarraf
Jul 15, 1983·Cancer·W K HongS Strong
Jan 1, 1981·Journal of Chronic Diseases·W O SpitzerB R Catchlove
Nov 1, 1994·Head & Neck·A A Forastiere
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H HochsterR Z Vinci
Feb 17, 1993·Journal of the National Cancer Institute·W J SlichenmyerS H Kaufmann
Citations
Sep 21, 2007·Cancer Chemotherapy and Pharmacology·Francesco CaponigroPatricia Pollard
Oct 26, 2006·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Nuray Bayar MulukA Nur Cakar
Aug 29, 2002·Cancer Investigation·Eric I SbarAlexandre Hageboutros
Jun 10, 2004·Human Pathology·Hilal HafianMichel Pluot
May 5, 2001·Expert Opinion on Pharmacotherapy·B Arun, E P Frenkel
Feb 16, 2005·Expert Opinion on Pharmacotherapy·Barbara A Murphy
Mar 11, 2005·Oncology Nursing Forum·Teresa T Goodell, Lillian M Nail
Apr 2, 1999·International Journal of Oral and Maxillofacial Surgery·S N RogersJ A Woolgar
Jan 6, 2005·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Nuray Bayar MulukCan Koç
May 21, 2008·BJU International·Daniel M BerneyCathy Corbishley
Oct 12, 2000·Medical and Pediatric Oncology·C Rodriguez-GalindoP J Houghton
Jun 1, 2004·American Journal of Clinical Oncology·Stephen M AnsellJoseph Rubin
Mar 10, 2001·American Journal of Clinical Oncology·B A MurphyA Forastiere
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J NemunaitisD Kirn
Jan 7, 1999·The Annals of Pharmacotherapy·R J Cersosimo